Oncotarget · 2015 · 13 citations · 24 references
MedicineOncologyPharmacologyCancer PharmacologyChemotherapyMolecular OncologyBreast Cancer PharmacotherapyHer2-positive Breast CancerTargeted Cancer TherapyBreast Cancer Resistance MechanismsCombination TherapyGamma Secretase InhibitionHer2 Gene AmplificationHer2 InhibitorsHer2-positive Breast Cancer TherapyPhosphatidylinositol 3-Kinase-akt PathwayPi3k-akt Signaling Pathway
// Feng Su 1 , Shilin Zhu 2 , Jinlan Ruan 3 , Yagmur Muftuoglu 4 , Longbo Zhang 5 , Qianying Yuan 3, 4 1 Department of Emergency, Xiangya Hospital, Central South University, Changsha, China 2 The Second Affiliated Hospital, Hunan University of Chinese Medicine, Changsha, China 3 Department of Pharmacology, Huazhong University of Science and Technology, Wuhan, China 4 Department of Pharmacology, Yale University School of Medicine, New Haven, CT, USA 5 Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China Correspondence to: Longbo Zhang, e-mail: zhanglb@csu.edu.cn , longbo.zhang@yale.edu Qianying Yuan, e-mail: qianying.yuan@yale.edu , qianying.yuan@gmail.com Keywords: RY10-4, resistance, Notch, breast cancer Received: July 01, 2015 Accepted: December 01, 2015 Published: December 26, 2015 ABSTRACT RY10-4, a novel protoapigenone analog, shows potent cytotoxicity against human breast cancer cells. However, breast cancer cell lines overexpressing human epidermal growth factor receptor 2 (HER2), SKBR3 and BT474, showed less sensitivity to RY10-4 when compared to breast cancer cells lines expressing lower levels of HER2, such as MDA-MB-231 and MCF-7 cells. This was associated with aberrant hyperactivity in Notch signaling in cells treated with RY10-4, since treatment with RY10-4 causes an increase in Notch activity by 2-to3.5-fold in SKBR3 and BT474 cell lines. The increase in activity was abrogated with a γ-secretase inhibitor, DAPT, or with Notch1 small-interfering RNA (si-Notch1). Cell proliferation was inhibited more effectively by RY10-4 plus DAPT or si-Notch1 than either agent alone. RY10-4 plus DAPT increases apoptosis in both HER2-overexpressing cell lines by two-fold compared to RY10-4 alone, while DAPT alone has no significant effects on apoptosis. In addition, we previously found RY10-4 could inhibit tumor growth through the PI3K/AKT pathway. Here we report that the combination of RY10-4 and DAPT exhibit additive suppression on AKT phosphorylation, contributing to the anti-cancer effects. In an animal model, this combination therapy inhibits the growth of SKBR3 tumor xenografts in nude mice to a greater extent than treatment with either reagent alone. These results indicate that the aberrant activation of Notch signaling impedes the inhibitory effect of RY10-4 on HER2-amplified cell proliferation. Furthermore, these adverse effects can be prevented by treatment combining RY10-4 with a Notch pathway inhibitor.
24
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Edward H. Romond, Edith A. Perez, John Bryant et al. · New England Journal of Medicine · 2005 · 5.4K citations · Full text
Medicine, Oncology, Pharmacotherapy +17
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Martine Piccart, Marion Procter, Brian Leyland‐Jones et al. · New England Journal of Medicine · 2005 · 5.1K citations · Full text
Medicine, Oncology, Pharmacology +16
Trastuzumab-Induced Hepatotoxicity: A Case Report
D. Vucicevic, Elizabeth J. Carey, Nina J. Karlin · Breast Care · 2013 · 4.4K citations · Full text
Medicine, Oncology, Pharmacotherapy +17
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Charles E. Geyer, John Forster, Deborah Lindquist et al. · New England Journal of Medicine · 2006 · 3.5K citations · Full text
Medicine, Oncology, Pharmacology +17
Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia
Teresa Palomero, Maria Luisa Sulis, Maria S. Cortina et al. · Nature Medicine · 2007 · 872 citations · Full text